Skip to main content
. Author manuscript; available in PMC: 2017 Nov 16.
Published in final edited form as: Pharmacol Ther. 2012 Mar 28;135(1):54–70. doi: 10.1016/j.pharmthera.2012.03.007

Table IV.

Summary of ER knockout mice.

Gene Knockout Mutation Company Original Paper Names Used by Review References
esr1 ERα disruption, exon 2 Lubhan, 1993 Chapel Hill (CH), αERKO 1, 2, 3, 4
esr1 ERα disruption, exon 2 Taconic (discontinued) Lubhan, 1993 5
esr1 ERα disruption, exon 2 Jackson Labs Lubhan, 1993
esr1 ERα deletion, exon 3 Dupont, 2000 Strasbourg (ST), ERαKO, Ex3αERKO 6
esr2 ERβ disruption, Krege, 1998 Chapel Hill, 2, 3, 7, 8
exon 3 ERβKOCH, βERKO
esr2 ERβ disruption, exon 3 Taconic (discontinued) Krege, 1998 5, 9, 10
esr2 ERβ disruption, exon 3 Jackson Labs Krege, 1998
esr2 ERβ disruption, exon 3 Krege, 1998 Transfer to Karolinska Institute, ERβKOKI
esr2 ERβ disruption, exon 3 Dupont, 2000 Strasbourg, ERβKOST 6
esr2 ERβ Translational block, post-codon 19 Shughrue, 2002 Wyeth, ERβKOWY
esr2 ERβ deletion, exon 3 Antal, 2008 ERβSTL-/L-
esr1+esr2 ERα+ERβ cross α, β KOCH Couse, 1999 Chapel Hill 11, 12
esr1+esr2 ERα+ERβ cross α, β KOST Dupont, 2000 Strasbourg
esr1+esr2 ERα+ERβ cross αKOCH, βKOWY Shughrue, 2002 Wyeth